Seiichiro Katagiri

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Recent advances in the treatment of chronic myeloid leukemia

Recent advances in the treatment of chronic myeloid leukemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 03, 2026

Sustained molecular response after discontinuation of ropeginterferon alfa-2b in a young patient with polycythemia vera

Sustained molecular response after discontinuation of ropeginterferon alfa-2b in a young patient with polycythemia vera

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 29, 2026

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

Journal: British journal of haematology

Published: March 12, 2026

Overview

Overview

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 04, 2026

Bi-directional association between RUNX1::RUNX1T1 and KIT mutations in acute myeloid leukemia: A multicenter genomic profiling study.

Bi-directional association between RUNX1::RUNX1T1 and KIT mutations in acute myeloid leukemia: A multicenter genomic profiling study.

Journal: Leukemia research

Published: December 21, 2025

Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.

Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.

Journal: International journal of hematology

Published: December 03, 2025

Reciprocal Clonal Dynamics of Independent FLT3 D835V-Positive Acute Myeloid Leukemia and Chronic Myeloid Leukemia With Gilteritinib.

Reciprocal Clonal Dynamics of Independent FLT3 D835V-Positive Acute Myeloid Leukemia and Chronic Myeloid Leukemia With Gilteritinib.

Journal: EJHaem

Published: November 27, 2025

Aplastic anaemia with small paroxysmal nocturnal haemoglobinuria clones developing during osimertinib therapy for non-small cell lung cancer.

Aplastic anaemia with small paroxysmal nocturnal haemoglobinuria clones developing during osimertinib therapy for non-small cell lung cancer.

Journal: Leukemia research reports

Published: October 19, 2025

Comparison of IPSS-R and IPSS-M in newly diagnosed myelodysplastic neoplasms: a single-center study

Comparison of IPSS-R and IPSS-M in newly diagnosed myelodysplastic neoplasms: a single-center study

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: February 09, 2025

TP53 deletion is associated with poor survival of adult ALK-positive ALCL patients receiving CHOP-based chemotherapy.

TP53 deletion is associated with poor survival of adult ALK-positive ALCL patients receiving CHOP-based chemotherapy.

Journal: Annals of hematology

Published: December 21, 2024

Aplastic anemia associated with osimertinib: Analysis of the FDA adverse event reporting system.

Aplastic anemia associated with osimertinib: Analysis of the FDA adverse event reporting system.

Journal: International journal of clinical pharmacology and therapeutics

Published: November 20, 2024

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma.

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma.

Journal: Cancer science

Published: September 27, 2024

Showing 1-12 of 58

Last Updated: 09/26/2026